 |
|
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online 2022 Dec 5 DOI: https://doi.org/10.3350/cmh.2022.0318
|
|
Citations to this article as recorded by
 Genetic Variation in Angiotensin II Type 1 Receptor Is Linked to Lipid Levels and Hepatic Steatosis in Alcohol-Associated Liver Disease, but Not to Cirrhosis or Hepatocellular Carcinoma
Hans Dieter Nischalke, Franziska Schmalz, Janett Fischer, Christine Möller, Madlen Matz-Soja, Benjamin Krämer, Bettina Langhans, Jacob Nattermann, Thomas Berg, Christian P. Strassburg, Philipp Lutz
Gastroenterology Insights.2024; 15(1): 19. CrossRef Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
Fernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, Reginald Frye, Eddison Godinez Leiva, Kenneth Cusi
JHEP Reports.2024; 6(7): 101092. CrossRef The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
Carlos Jose Pirola, Silvia Sookoian
Clinical and Molecular Hepatology.2024; 30(2): 174. CrossRef Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population
Young Lee, Eun Ju Cho, Eun Kyung Choe, Min-Sun Kwak, Jong In Yang, Seung-Won Oh, Jeong Yoon Yim, Goh Eun Chung
Scientific Reports.2024;[Epub] CrossRef Genetic predisposition to metabolic dysfunction-associated fatty liver disease
O.E. Abaturov, A.O. Nikulina
CHILD`S HEALTH.2024; 19(3): 162. CrossRef Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making
Carlos J Pirola, Silvia Sookoian
Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo
International Journal of Molecular Sciences.2023; 24(13): 10718. CrossRef New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeongjun Song
Nutrients.2023; 15(18): 3970. CrossRef Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population
Jingwei Zhang, Shijie Ma, Wei Zhou, Jing Feng, Yuwei Kang, Wei Yang, Heping Zhang, Fei Deng
Toxicology and Applied Pharmacology.2023; 481: 116770. CrossRef
|